Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: RE: Difinitive valuation method - Mich

RE: Difinitive valuation method - Mich

posted on Apr 20, 2006 10:13AM
Actually, $60mm of the $70mm in licensing rev`s were recognized in Q3. So while it is true that 9-month rev`s overall were $70mm, 86% of those rev`s came in the 3rd qtr. and thus an argument can be made that go-forward rev`s on a quarterly basis could be closer to what we just experienced in the most recent qtr, as opposed to the six months prior. But again, caution when using extrapolations on PTSC revenue projetions must be observed due to their vast unpredictability (thus far anyhow).

MW

Share
New Message
Please login to post a reply